Phillip P. Chan - Nov 18, 2025 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Role
Chief Executive Officer, Director
Signature
/s/ Phillip P. Chan
Stock symbol
CTSO
Transactions as of
Nov 18, 2025
Transactions value $
$64,000
Form type
4
Date filed
11/20/2025, 09:09 PM
Previous filing
Aug 8, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Chan Phillip P. Chief Executive Officer, Director C/O CYTOSORBENTS CORPORATION, 305 COLLEGE ROAD EAST, PRINCETON /s/ Phillip P. Chan 2025-11-20 0001442786

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTSO Common Stock Award $64K +100K +7.23% $0.64 1.48M Nov 18, 2025 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported on this Form 4 reflects an open market purchase made by the reporting person.
F2 Includes: (i) the following restricted stock units ("RSUs") that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;
F3 (continued from footnote 2) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 96,000 RSUs granted on April 2, 2024 and of which 48,000 remain unvested as of the date hereof;
F4 (continued from footnote 3) (iv) 105,600 RSUs which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and (v) 1,113,363 shares of Common Stock owned by the Reporting Person.